News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News J&J could pay $1 billion for oncolytic virus firm BeneVir J&J follows Merck & Co, and BMS with oncolytic virus acquisition
Digital NHS IT glitch ‘caused deaths by cancelling cancer screening’ Health secretary Jeremy Hunt to launch inquiry
News Novartis matches Gilead on price in new CAR-T use Novartis won't offer 'money back' scheme because of delayed effect
News Ipsen takes on BMS as kidney cancer pill launches in EU Cabometyx could take market share from Opdivo
News BI to trial SIRP drug with in-house PD-1 inhibitor Boehringer Ingelheim has revealed further details about its plans for a new kind of cancer immunotherapy licensed in from biotech OSE Therapeutics at the beginning of last month, saying it
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
